Open AccessHigh rates of durable response are achieved with imatinib after treatment with interferon plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial
Author(s) -
François Guilhot,
Brian J. Druker,
Richard A. Larson,
Insa Gathmann,
Charlene So,
Roger J. Waltzman,
Stephen G. O’Brien
Publication year - 2009
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2009.010629
Subject(s) - medicine , imatinib , cytarabine , imatinib mesylate , myeloid leukemia , randomized controlled trial , oncology , gastroenterology , surgery
Imatinib is the standard of care for newly diagnosed chronic-phase chronic myeloid leukemia. The largest randomized clinical trial of imatinib was the multinational IRIS trial in which 1106 patients were randomized to receive either imatinib 400 mg/day or a standard regimen of interferon-alpha plus cytarabine.